Kyverna Therapeutics
Fludarabine (FLU)(Kyverna Therapeutics)은 Leukemia 표적 치료제로, Fanconi Anemia; Severe Aplastic Anemia 영역에서 개발·상용화 중입니다. 작용기전: CAR-T therapy induced profound, durable responses in extremely severe patients with seropositive PIRR. Phase 2에서 효능·안전성 신호를 검증 중입니다. Background: * Melanoma antigen recognized by T-cells (MART)-1 is a protein present in melanoma cells. * An experimental…. 차별점: uniquely interrogate the early immune factors associated with clinical outcome.
Leukemia
Fanconi Anemia; Severe Aplastic Anemia
Recruiting
CAR-T for Large Cell Lymphoma
uniquely interrogate the early immune factors associated with clinical outcome
CAR-T therapy induced profound, durable responses in extremely severe patients with seropositive PIRR
T cell activation
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Kyverna Therapeutics
Fludarabine (FLU)(Kyverna Therapeutics)은 Leukemia 표적 치료제로, Fanconi Anemia; Severe Aplastic Anemia 영역에서 개발·상용화 중입니다. 작용기전: CAR-T therapy induced profound, durable responses in extremely severe patients with seropositive PIRR. Phase 2에서 효능·안전성 신호를 검증 중입니다. Background: * Melanoma antigen recognized by T-cells (MART)-1 is a protein present in melanoma cells. * An experimental…. 차별점: uniquely interrogate the early immune factors associated with clinical outcome.
Leukemia
Fanconi Anemia; Severe Aplastic Anemia
Recruiting
CAR-T for Large Cell Lymphoma
uniquely interrogate the early immune factors associated with clinical outcome
CAR-T therapy induced profound, durable responses in extremely severe patients with seropositive PIRR
T cell activation
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.